David Sinclair’s ER-100 Clinical Trial: First Human Data on Glaucoma and Epigenetic Reprogramming

Conceptual close-up of a human eye with abstract neural and molecular imagery representing vision and epigenetic research.

Protecting your vision means protecting the freedom to read, drive, travel, and enjoy the people and activities you love. That is why a new clinical trial in glaucoma is drawing attention far beyond eye care. On June 9, 2026, Life Biosciences, co-founded by Harvard Medical School geneticist Dr. David Sinclair, announced that the first participant…

Read More

From Biological Age to Healthspan: How Clinics Are Tracking Aging More Precisely

Blood test tubes to represent biological age testing

Most people think about aging in birthdays and decades. But inside the body, aging is far more dynamic. Two people can be the same chronological age and have completely different levels of cardiovascular health, metabolic function, cognitive performance, recovery capacity, and inflammation. That is where biological age testing is changing the conversation around longevity. At…

Read More

Targeting the Hallmarks of Aging: Why Longevity Medicine Must Treat Root Causes, Not Just Disease

Smiling older man with glasses, for an article about the hallmarks of aging

The Fundamental Question Most of modern medicine treats symptoms or diseases after they appear.But what if we could intervene earlier—at the root biological processes that drive aging itself? That is exactly what targeting the hallmarks of aging allows us to do. Instead of managing heart disease, diabetes, arthritis, or Alzheimer’s as separate conditions, we can…

Read More

NEO-7: The Future of Precision Longevity Medicine

mature adult in ski gear

If you’ve ever wished your health plan could be designed uniquely for you—your genes, your environment, your goals—you’re not alone. For decades, longevity medicine has focused on generalized protocols: same supplements, same peptides, same diet advice. But the truth is, what works wonders for one person may do little for another. That’s why I’m thrilled…

Read More